MediBeacon
- Company typePrivate
- Founded2012
- HeadquartersSt Louis, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
MediBeacon firmographics
Firmographics- Name
- MediBeacon
- Legal name
- MediBeacon Inc.
- Website
- https://medibeacon.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
MediBeacon industry classification
Industry- Product category
- Optical Diagnostics / Kidney Function Assessment
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)
- akta.pro secondary industries
- Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine) (HLAHAOAE), Urinalysis & Routine Screening Diagnostics (HLAHAAAG)
Keywords
Where MediBeacon is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
MediBeacon business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- TGFR System Hardware Sales: Sale of TGFR monitors and reusable sensors to healthcare facilities, academic medical centers, and hospitals for point-of-care kidney function assessment.
- Lumitrace (Relmapirazin) Tracer Agent: Single-use injectable fluorescent tracer agent (Lumitrace) used with the TGFR system. The tracer agent is a consumable that must be administered during each GFR assessment session.
- Preclinical Products: Sale of Preclinical MX devices and related consumables (fluorescent tracer agents, measurement codes) for preclinical animal research. The product enables longitudinal GFR measurements in conscious, freely-moving animals.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical device pricing for healthcare institutions |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
MediBeacon product offering
Product offeringCore offering
MediBeacon develops and commercializes fluorescent tracer agent-based transdermal diagnostic systems, with its core product being the TGFR (Transdermal Glomerular Filtration Rate) System that includes Lumitrace (relmapirazin) injection, a TGFR Monitor, a Reusable Sensor, and a Disposable Ring for non-invasive point-of-care kidney function assessment. The company also offers the Preclinical MX device and related software for longitudinal GFR measurement in conscious, freely-moving laboratory animals, alongside a research pipeline extending the fluorescent tracer platform into gastrointestinal permeability, ocular angiography, and surgical visualization applications.
Product overview
MediBeacon is a medical technology company offering a portfolio of fluorescent tracer agent-based transdermal detection systems. The core product is the TGFR (Transdermal Glomerular Filtration Rate) System, which includes Lumitrace (relmapirazin) injection as the fluorescent tracer agent, the TGFR Monitor for displaying data, the TGFR Reusable Sensor for transdermal detection, and the TGFR Disposable Ring as a single-use component. The system received FDA approval in December 2025, CE Mark in March 2026, and China NMPA approval in October 2025. For preclinical research, the company offers the Preclinical MX device along with Lab 3 and Studio 3 software. Applications span nephrology (kidney function assessment), gastroenterology (GI permeability), ophthalmology (ocular angiography), and surgery (ureter visualization).
Differentiator
Problem solved
Functional benefit
Brands
- TGFR: Transdermal Glomerular Filtration Rate system for kidney function assessment
- Lumitrace
- 敏狄康 (Mindikang)
Products and services
- MediBeacon TGFR System Transdermal Glomerular Filtration Rate measurement system that non-invasively assesses kidney function by measuring fluorescent tracer agent clearance through transdermal detection. The system includes Lumitrace injection, a monitor, and reusable sensor, and is FDA-approved for assessing GFR in adult patients with impaired or normal renal function.
- Lumitrace (relmapirazin) Injection Exogenous pyrazine-based fluorescent tracer agent administered as an IV bolus injection. Engineered to be inert, highly fluorescent, and have clearance properties of a GFR tracer agent, with negligible protein binding, negligible metabolism, and physiologic pH formulation. Detected transdermally to measure kidney function.
- MediBeacon TGFR Monitor Medical device that displays fluorescence data collected during monitoring sessions. The Average Session GFR is displayed at the end of a full session, which may last 6 to 24 hours depending on renal function. CE Mark certified under EU MDR as a Class IIa device.
- MediBeacon TGFR Reusable Sensor Non-invasive sensor engineered to measure the intensity of Lumitrace injection 2.5 times per second continuously throughout the monitoring session. Placed on the patient's skin to measure fluorescence transdermally, automatically adjusting for different skin tones and compensating for tissue properties. Validated across diverse Fitzpatrick skin types and CE Mark certified under EU MDR.
- MediBeacon TGFR Disposable Ring Single-use component intended to be assembled with the TGFR Reusable Sensor and attached to the patient's skin during a TGFR session. Part of the TGFR System cleared under PMA No. P230019.
- MediBeacon Preclinical MX Transdermal GFR monitoring system for preclinical (animal) nephrology research. Enables longitudinal GFR measurements in conscious, freely-moving mice, rats, and larger animals. Used by leading medical schools, research institutes, and pharmaceutical companies worldwide.
Quantifiable outcome
- Non-invasive GFR assessment without blood draws, urine sampling, or lab analysis
- +3 more outcomes
Companies that use MediBeacon
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
MediBeacon technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature6 records
MediBeacon partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Huadong Medicine Co., Ltd.coreExclusive commercialization partnership for Greater China. Huadong Medicine invested $30 million in 2019 and provided an additional $10 million in amended agreements in 2022. Huadong is a leading Chinese pharmaceutical company listed on Shenzhen Stock Exchange with integrated R&D, manufacturing, distribution, and sales capabilities across oncology, immunology, nephrology, diabetes, GI, and operating rooms.
- Washington University School of MedicineminorCollaboration with Washington University School of Medicine in St. Louis for research on childhood malnutrition and gut permeability. Funded by Bill & Melinda Gates Foundation Grand Challenges Explorations Phase II grant of $1.1 million to Washington University. Led by Dr. Phillip I. Tarr, Director of Pediatric Gastroenterology.
- Mayo ClinicminorResearch collaboration with Mayo Clinic for gut permeability studies using MediBeacon fluorescent tracer agent-based systems.
- Imperial College LondonminorResearch partnership with investigators at Imperial College London for gastrointestinal permeability research.
- Cincinnati Children's Hospital Medical CenterminorDr. Stuart L. Goldstein serves as MediBeacon Director of Clinical Development. He is Professor of Pediatrics and Director of the Center for Acute Care Nephrology at Cincinnati Children's Hospital.
Scale indicators14 records
Recent moves6 records
Expansion highlights7 records
MediBeacon competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers: Siemens offers laboratory creatinine assays and POC blood gas analyzers with creatinine modules used for GFR estimation. As a major clinical diagnostics incumbent, Siemens competes across the workflow where MediBeacon's transdermal system could displace conventional creatinine-based GFR assessment.
- Roche Diagnostics: Roche offers the cobas platform for laboratory creatinine testing and eGFR calculation, alongside a broader menu of clinical chemistry assays. As the world's largest diagnostics company, Roche represents the established infrastructure that MediBeacon's transdermal system would need to displace or complement.
- Fresenius Medical Care: Fresenius is the global leader in dialysis services and renal care products, serving the same CKD and ESRD patient population MediBeacon targets. While Fresenius's core business is dialysis rather than diagnostics, it represents the dominant commercial force in renal care that MediBeacon must position against in GFR assessment.
- bioMérieux (including Astute Medical): bioMérieux acquired Astute Medical, whose NephroCheck test measures urinary biomarkers (TIMP-2, IGFBP7) for acute kidney injury risk assessment. Directly comparable to MediBeacon in the kidney function diagnostic category, though focused on AKI prediction rather than continuous GFR measurement.
- QuidelOrtho: QuidelOrtho (formed by merger of Quidel and Ortho Clinical Diagnostics) provides clinical laboratory diagnostics including creatinine assays used for GFR estimation. Comparable as an incumbent diagnostics provider in the kidney function testing workflow.
- Abbott Diagnostics: Abbott offers the i-STAT system for POC creatinine measurement, a foundational alternative to transdermal GFR in many hospital settings. As a major diagnostics incumbent, Abbott competes across the broader renal assessment workflow and benefits from established hospital relationships and reimbursement infrastructure.
Direct peers
- Nova Biomedical: Nova Biomedical manufactures point-of-care creatinine analyzers (StatSensor Creatinine) that provide rapid GFR estimates at the bedside. Direct comparability to MediBeacon in the POC kidney function assessment category, though Nova's approach uses blood-based creatinine rather than fluorescent tracer clearance.
Emerging players
- Quanterix: Quanterix offers ultra-sensitive biomarker detection platforms (Simoa) used in research and clinical applications including nephrology. Comparable as an emerging diagnostics platform company developing novel measurement technologies for kidney disease and adjacent therapeutic areas.
- Metabolon: Metabolon applies metabolomics profiling to identify biomarkers for chronic kidney disease progression and other conditions. Comparable as an emerging biomarker discovery and diagnostic company targeting the same renal patient population, though using mass spectrometry rather than fluorescent tracer approaches.
- Spectral Medical: Spectral Medical develops diagnostics for acute kidney injury and sepsis, including the PMX endotoxin removal column. Comparable as an emerging company targeting renal diagnostics with novel technology approaches, though Spectral focuses on therapeutic intervention rather than continuous monitoring.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
MediBeacon social profiles
Digital presenceMediBeacon compliance and trust
Trust signalCompliance3 records
MediBeacon financial estimates
Financial estimateRevenue estimate
Valuation estimate
MediBeacon leadership team
Management profileNumber of profiles
Profiles7 records
MediBeacon subsidiaries and ownership
Company hierarchySubsidiaries1 record
MediBeacon funding detail
Funding detailFunding overview
Funding rounds10 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MediBeacon M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MediBeacon
What does MediBeacon do?
MediBeacon develops and commercializes fluorescent tracer agent-based transdermal diagnostic systems, with its core product being the TGFR (Transdermal Glomerular Filtration Rate) System that includes Lumitrace (relmapirazin) injection, a TGFR Monitor, a Reusable Sensor, and a Disposable Ring for non-invasive point-of-care kidney function assessment. The company also offers the Preclinical MX device and related software for longitudinal GFR measurement in conscious, freely-moving laboratory animals, alongside a research pipeline extending the fluorescent tracer platform into gastrointestinal permeability, ocular angiography, and surgical visualization applications.
Is MediBeacon a public or private company?
MediBeacon is a private company. It is classified as corporate owned and is currently operating.
When was MediBeacon founded?
MediBeacon was founded in 2012. It employs 11 to 50 people.
Where is MediBeacon based?
MediBeacon is headquartered in St Louis, United States, in the North America region.
How does MediBeacon make money?
Three revenue lines are on record. TGFR System Hardware Sales are the primary driver. The others are lumitrace (Relmapirazin) Tracer Agent and preclinical Products.
Who are MediBeacon's main competitors?
Broad incumbents on record are Siemens Healthineers, Roche Diagnostics, Fresenius Medical Care, bioMérieux (including Astute Medical), QuidelOrtho and Abbott Diagnostics. Nova Biomedical is listed as a direct peer. Emerging players are Quanterix, Metabolon and Spectral Medical.
Does MediBeacon have an API?
No public API is recorded for MediBeacon.
What industry is MediBeacon in?
MediBeacon's product category is Optical Diagnostics / Kidney Function Assessment. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status), with a secondary code of HLAHAOAE, Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine). Its NAICS code is 325413 and its SIC code is 2835.